Durham, NC, November 1 , 2017 – GeneCentric Therapeutics Founder and CEO, Dr. Myla-Lai Goldman, will be featured today on the radio show ”Radio In Vivo: Your Link to the Triangle Science Community!”, from 11:00am-12:00pm, ET, on WCOM – FM103.5, based in Carrboro, NC.
Author Archives:
Mayhew G, Perou C, Hayes N, Lai-Goldman M, and Faruki H.
Durham, NC, October 26, 2017— GeneCentric Therapeutics announced today that it will present data on the potential of non-small cell lung cancer (NSCLC) biologic subtypes based on its Cancer Subtyping Platform (CSP®) to provide novel biomarkers for response to PARP inhibitors. The data will be presented at a poster session during the 2017 American Association for Cancer Research – National Cancer Institute – European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Therapeutics being held October 27-30, 2017 at the Philadelphia Convention Center, Philadelphia, PA.
GeneCentric Therapeutics, Inc., a precision medicine company dedicated to accelerating drug development by redefining the advanced classification of cancers, today announced the appointments of Walter M. Capone as Chief Business Officer and Ellen Lubman to the company’s Board of Directors.
Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M.
Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc. today announced a biomarker research collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform (CSP™) might be able to identify translational biomarkers for Opdivo (nivolumab)…
Faruki H, Mayhew G, Hayes N, Serody J, Perou C., Lai-Goldman M.
Faruki H, Mayhew G, Feng C, Wilkerson M, Horten B, et al.
GeneCentric to Present Data at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
Mayhew G, Hayes N, Perou C, Lai-Goldman M, Faruki H.
GeneCentric Diagnostics, Inc., a company devoted to changing the taxonomy of cancer through the analysis of tumor genomics, today announced that it will present new data on its lung cancer subtyping product, LSP™ 120, at the Association for Molecular Pathology (AMP) 2015 Annual Meeting being held November 5-7, 2015 at the Austin Convention Center in Austin, Texas.
Mayhew G, Hayes N, Perou C, Lai-Goldman M, Faruki H.
GeneCentric Diagnostics, Inc., a company devoted to changing the taxonomy of cancer through an integrated analysis of tumor pathology and genomics, today announced that it will present new data on its lung cancer subtyping product, LSP™ 120, at the 16th World Conference on Lung Cancer being held September 6-9, 2015 at the Colorado Convention Center in Denver, CO.
The Cancer Genome Atlas Research Network (TCGA)
Zhao N, Wilkerson MD, Shah U, Yin X, Wang A, Hayward MC, Roberts P, Lee CB, Parsons AM, Thorne LB, Haithcock BE, Grilley-Olson JE, Stinchcombe TE, Funkhouser WK, Wong KK, Sharpless NE, Hayes DN.
The Cancer Genome Atlas Research Network (TCGA)
Wilkerson MD, Schallheim JM, Hayes DN, Roberts PJ, Bastien RRL et al.
Walter V, Yin X, Wilkerson MD, Cabanski CR, Zhao N, et al.
Grilley-Olson JE, Hayes DN, Moore DT, Leslie KO, Wilkerson MD, et al.
The Cancer Genome Atlas Research Network (TCGA)